Acute Myeloid Leukemia with Flt3-itd Mutation

• CLINICAL_TRIALS trial_result · 2026-01-05
  Clinical Trial Update: A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]

  A Phase 1/2 study evaluating gilteritinib in combination with chemotherapy for pediatric and young adult FLT3-ITD–positive relapsed/refracto…

• CLINICAL_TRIALS research · 2025-12-05
  Clinical Trial Update: Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML [Phase 1]

  This update describes an ongoing Phase 1 study evaluating Vyxeos plus gilteritinib for relapsed or refractory FLT3-mutated acute myeloid leu…

• CLINICAL_TRIALS trial_result · 2024-09-19
  Clinical Trial Update: Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

  A Phase 1/2 trial evaluating venetoclax plus quizartinib in FLT3-mutated acute myeloid leukemia was terminated, with results posted.

• CLINICAL_TRIALS trial_result · 2022-06-27
  Clinical Trial Update: A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission [Phase 2]

  Phase 2 trial evaluating gilteritinib as maintenance therapy after induction/consolidation in adults with FLT3-ITD acute myeloid leukemia in…